Michael Benkowitz Sells 10,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $956,195.85. This represents a 79.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 10th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00.
• On Monday, February 3rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $353.64, for a total transaction of $3,536,400.00.
• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $370.71, for a total transaction of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.91, for a total transaction of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.62, for a total transaction of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $356.68, for a total transaction of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $361.95, for a total transaction of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00.

United Therapeutics Price Performance

UTHR stock opened at $367.36 on Friday. United Therapeutics Co. has a one year low of $214.52 and a one year high of $417.82. The stock has a market cap of $16.40 billion, a PE ratio of 16.13, a P/E/G ratio of 0.97 and a beta of 0.57. The firm has a 50 day simple moving average of $362.70 and a two-hundred day simple moving average of $359.94.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. Wealthfront Advisers LLC grew its stake in United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after buying an additional 18,313,424 shares in the last quarter. Norges Bank purchased a new position in United Therapeutics in the 4th quarter worth approximately $151,764,000. FMR LLC grew its stake in United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after buying an additional 393,777 shares in the last quarter. World Investment Advisors LLC purchased a new position in United Therapeutics in the 3rd quarter worth approximately $139,206,000. Finally, Thrivent Financial for Lutherans grew its stake in United Therapeutics by 1,325.5% in the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock worth $72,085,000 after buying an additional 189,967 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on UTHR. The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Argus boosted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH boosted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.